Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP7A1 | P22680 | 1/20 | 0.38 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635298 | 0.96 | KDM2B (0.41) | KDM2BCYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL2637431 | 0.90 | MEN1 (0.45) | KDM2BCYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL2635545 | 0.89 | MEN1 (0.46) | KDM2BMEN1KMT2APOLBMAPT | |
| SCHEMBL2635247 | 0.88 | KDM2B (0.41) | KDM2BMEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL2635267 | 0.85 | HTT (0.47) | MEN1KMT2ACYP3A4SMN1; SMN2USP2 | |
| SCHEMBL2635511 | 0.84 | MEN1 (0.46) | KDM2BMEN1KMT2APOLBMAPT | |
| SCHEMBL2636070 | 0.84 | KDM2B (0.41) | KDM2BMEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL2637486 | 0.83 | MEN1 (0.46) | KDM2BCYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL2634767 | 0.81 | HTT (0.47) | MEN1KMT2ACYP3A4SMN1; SMN2USP2 | |
| SCHEMBL2635036 | 0.79 | S100A9 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | claimed |
| EP-2569317-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | claimed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | claimed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| EP-2569317-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109711-A1 | NOVEL COMPOUNDS | TRPV2, CACNA1C, CACNA1B | KDM2B 4602/4885CYP11B1 4299/4885CYP11B2 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.